The role played by stereochemistry in the C2-substituent (left part) on the S-DABO scaffold for anti-HIV-1 activity has been investigated for the first time. A series of S-DABO analogues, where the double bond in the C2-substituent is replaced by an enantiopure isosteric cyclopropyl moiety, has been synthesized, leading to the identification of a potent lead compound endowed with picomolar activity against RT (wt) and nanomolar activity against selected drug-resistant mutants. Molecular modeling calculation, enzymatic studies, and surface plasmon resonance experiments allowed us to rationalize the biological behavior of the synthesized compounds, which act as mixed-type inhibitors of HIV-1 RT K103N, with a preferential association to the enzyme-substrate complex. Taken together, our data show that the right combination of stereochemistry on the left and right parts (C6-substituent) of the S-DABO scaffold plays a key role in the inhibition of both wild-type and drug-resistant enzymes, especially the K103N mutant.

Discovery of Chiral Cyclopropyl Dihydro-Alkylthio-Benzyl-Oxopyrimidine (S-DABO) Derivatives as Potent HIV-1 Reverse Transcriptase Inhibitors with High Activity Against Clinically Relevant Mutants / Radi, Marco; Giovanni, Maga; Maddalena, Alongi; Lucilla, Angeli; Alberta, Samuele; Samantha, Zanoli; Luca, Bellucci; Andrea, Tafi; Gianni, Casaluce; Gianluca, Giorgi; Mercedes Armand, Ugon; Emmanuel, Gonzalez; José A., Esté; Mireille, Baltzinger; Guillaume, Bec; Philippe, Dumas; Eric, Ennifar; Maurizio, Botta. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 52:(2009), pp. 840-851. [10.1021/jm801330n]

Discovery of Chiral Cyclopropyl Dihydro-Alkylthio-Benzyl-Oxopyrimidine (S-DABO) Derivatives as Potent HIV-1 Reverse Transcriptase Inhibitors with High Activity Against Clinically Relevant Mutants

RADI, Marco;
2009-01-01

Abstract

The role played by stereochemistry in the C2-substituent (left part) on the S-DABO scaffold for anti-HIV-1 activity has been investigated for the first time. A series of S-DABO analogues, where the double bond in the C2-substituent is replaced by an enantiopure isosteric cyclopropyl moiety, has been synthesized, leading to the identification of a potent lead compound endowed with picomolar activity against RT (wt) and nanomolar activity against selected drug-resistant mutants. Molecular modeling calculation, enzymatic studies, and surface plasmon resonance experiments allowed us to rationalize the biological behavior of the synthesized compounds, which act as mixed-type inhibitors of HIV-1 RT K103N, with a preferential association to the enzyme-substrate complex. Taken together, our data show that the right combination of stereochemistry on the left and right parts (C6-substituent) of the S-DABO scaffold plays a key role in the inhibition of both wild-type and drug-resistant enzymes, especially the K103N mutant.
2009
Discovery of Chiral Cyclopropyl Dihydro-Alkylthio-Benzyl-Oxopyrimidine (S-DABO) Derivatives as Potent HIV-1 Reverse Transcriptase Inhibitors with High Activity Against Clinically Relevant Mutants / Radi, Marco; Giovanni, Maga; Maddalena, Alongi; Lucilla, Angeli; Alberta, Samuele; Samantha, Zanoli; Luca, Bellucci; Andrea, Tafi; Gianni, Casaluce; Gianluca, Giorgi; Mercedes Armand, Ugon; Emmanuel, Gonzalez; José A., Esté; Mireille, Baltzinger; Guillaume, Bec; Philippe, Dumas; Eric, Ennifar; Maurizio, Botta. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 52:(2009), pp. 840-851. [10.1021/jm801330n]
File in questo prodotto:
File Dimensione Formato  
2009_JMC.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.77 MB
Formato Adobe PDF
1.77 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2432269
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 40
social impact